Structure Therapeutics

Update in progress

GPCR (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company that develops and advances oral small-molecule therapies for chronic diseases with unmet needs, primarily in the United States. Its lead candidate, GSBR-1290, is a biased oral GLP-1 receptor agonist in Phase 2 for obesity and related conditions. The pipeline also includes ACCG-2671, ACCG-3535 (amylin receptor agonists in Phase 1), ANPA-0073 (APJ agonist), LTSE-2578 (LPA1 antagonist for IPF), and GIPR/GCGR programs for obesity and metabolic diseases. Formerly ShouTi Inc., founded in 2016, based in South San Francisco.

Company score

Sentiment: 0.28; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.10; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive